PolyNovo Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

PolyNovo yıllık ortalama 46.5% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar growing at 18.4% annual. Gelirler growing yılda ortalama 36.9% oranında artmaktadır. PolyNovo'in özkaynak karlılığı 7.8% ve net marjı 5.1%'dir.

Anahtar bilgiler

46.52%

Kazanç büyüme oranı

46.38%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	5.82%
Gelir büyüme oranı	36.87%
Özkaynak getirisi	7.82%
Net Marj	5.11%
Son Kazanç Güncellemesi	31 Dec 2024

Yakın geçmiş performans güncellemeleri

PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 03

Recent updates

Is There Now An Opportunity In PolyNovo Limited (ASX:PNV)?

May 08

NovoSorb MTX Launch And Global Expansion Will Strengthen Future Business Prospects

Mar 11 Launch of NovoSorb MTX in the U.S. and geographic expansion could drive revenue growth and diversify revenue sources.

PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 03

PolyNovo Limited's (ASX:PNV) Share Price Is Still Matching Investor Opinion Despite 37% Slump

Feb 26

An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 39% Undervalued

Feb 11

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

Gelir ve Gider Dağılımı

PolyNovo nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

ASX:PNV Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Dec 24	116	6	88
30 Sep 24	109	6	85
30 Jun 24	103	5	81
31 Mar 24	93	3	74
31 Dec 23	83	2	67
30 Sep 23	75	-2	61
30 Jun 23	66	-5	55
31 Mar 23	59	-6	51
31 Dec 22	53	-7	47
30 Sep 22	48	-4	39
30 Jun 22	42	-1	32
31 Mar 22	38	0	29
31 Dec 21	35	1	26
30 Sep 21	32	-2	27
30 Jun 21	29	-5	27
31 Mar 21	27	-5	26
31 Dec 20	25	-5	25
30 Sep 20	24	-5	23
30 Jun 20	22	-4	21
31 Mar 20	20	-4	19
31 Dec 19	18	-4	17
30 Sep 19	16	-3	15
30 Jun 19	14	-3	12
31 Mar 19	12	-4	11
31 Dec 18	9	-5	9
30 Sep 18	8	-5	9
30 Jun 18	7	-6	8
31 Mar 18	6	-6	8
31 Dec 17	5	-6	8
30 Sep 17	4	-6	8
30 Jun 17	4	-5	7
31 Mar 17	4	-4	6
31 Dec 16	5	-3	5
30 Sep 16	4	-3	5
30 Jun 16	3	-3	5
31 Mar 16	2	-3	4
31 Dec 15	0	-2	4
30 Sep 15	0	-2	3
30 Jun 15	0	-1	3
31 Mar 15	0	-2	3
31 Dec 14	0	-3	3
30 Sep 14	0	-3	3
30 Jun 14	0	-3	3

Kaliteli Kazançlar: PNV yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: PNV 'nin mevcut net kar marjları (5.1%) geçen yılın (1.9%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PNV son 5 yılda karlı hale geldi ve kazançlarını yıllık 46.5% oranında artırdı.

Büyüme Hızlandırma: PNV 'un son bir yıldaki kazanç büyümesi ( 270.2% ) 5 yıllık ortalamasını (yıllık 46.5% ) aşıyor.

Kazançlar vs. Sektör: PNV geçen yılki kazanç büyümesi ( 270.2% ) Medical Equipment sektörünün 19.6% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: PNV 'nin Özsermaye Getirisi ( 7.8% ) düşük olarak değerlendiriliyor.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/17 13:36
Gün Sonu Hisse Fiyatı	2025/05/16 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

PolyNovo Limited 10 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
John Hester	Bell Potter
Lyanne Harrison	BofA Global Research
Andrew Paine	CLSA

PolyNovo Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

First half 2025 earnings released: EPS: AU$0.005 (vs AU$0.004 in 1H 2024)

PolyNovo Limited to Report First Half, 2025 Results on Feb 24, 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Recent updates

Now 21% undervalued after recent price drop

Is There Now An Opportunity In PolyNovo Limited (ASX:PNV)?

NovoSorb MTX Launch And Global Expansion Will Strengthen Future Business Prospects

PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

PolyNovo Limited's (ASX:PNV) Share Price Is Still Matching Investor Opinion Despite 37% Slump

Price target decreased by 11% to AU$2.31

First half 2025 earnings released: EPS: AU$0.005 (vs AU$0.004 in 1H 2024)

Now 32% undervalued after recent price drop

Consensus EPS estimates fall by 10%

An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 39% Undervalued

PolyNovo Limited to Report First Half, 2025 Results on Feb 24, 2025

Insufficient new directors

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 21% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Now 20% undervalued

Price target increased by 7.0% to AU$2.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 24% undervalued

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 21% undervalued

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68